Innate Pharma ROA 2025

Innate Pharma Aktienanalyse

What does Innate Pharma do?

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Innate Pharma's Return on Assets (ROA)

Innate Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Innate Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Innate Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Innate Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Innate Pharma stock

What is the Return on Assets (ROA) of Innate Pharma this year?

The Return on Assets (ROA) of Innate Pharma is -0.04 undefined this year.

What was the ROA of Innate Pharma compared to the previous year?

The ROA of Innate Pharma has increased by -85.3% compared to the previous year.

What consequences do high ROA have for investors of Innate Pharma?

A high ROA is advantageous for investors of Innate Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Innate Pharma?

A low ROA can be unfavorable for investors of Innate Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Innate Pharma affect the company?

An increase in ROA of Innate Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Innate Pharma impact the company?

A reduction in the ROA of Innate Pharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Innate Pharma?

Some factors that can influence the ROA of Innate Pharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Innate Pharma important for investors?

The ROA of Innate Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Innate Pharma take to improve ROA?

To improve ROA, Innate Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Innate Pharma pay?

Over the past 12 months, Innate Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innate Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Innate Pharma?

The current dividend yield of Innate Pharma is .

When does Innate Pharma pay dividends?

Innate Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innate Pharma?

Innate Pharma paid dividends every year for the past 0 years.

What is the dividend of Innate Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innate Pharma located?

Innate Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innate Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innate Pharma from 1/29/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/29/2025.

When did Innate Pharma pay the last dividend?

The last dividend was paid out on 1/29/2025.

What was the dividend of Innate Pharma in the year 2024?

In the year 2024, Innate Pharma distributed 0 EUR as dividends.

In which currency does Innate Pharma pay out the dividend?

The dividends of Innate Pharma are distributed in EUR.